The Filing Desk

MediciNova vs Scienture

MediciNova MNOV · Scienture SCNX · Pharmaceuticals

MediciNova reported revenue of $0 million in fiscal 2025, about the same as Scienture's $0 million in fiscal 2025. MediciNova had an operating margin of -3242.5%, against -9867.9% at Scienture.

Side by side

MediciNovaScienture
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth—215.9%
Revenue growth a year, last 5 years—−52.8%
Gross margin—76.8%
Operating margin−3,242.5%−9,867.9%
Net margin−2,928.8%−9,618.0%
Free cash flow−$10M—
Free cash flow margin−2,395.4%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.0%320.1%
Last close$1.27$2.44
P/E at the last close——
Insider trades, last 12 monthssold $1.7 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MediciNovaScienture
Operating margin
Percent of revenue
MediciNovaScienture
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MediciNovaScienture

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MediciNova and Scienture pages.